Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Gynecologic Cancers
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
Would you consider giving hormone replacement therapy to a patient with atypical ductal hyperplasia with no alternative options to manage postmenopausal symptoms?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Does HER2 status or response to neoadjuvant therapy influence your decision to use ovarian function suppression in premenopausal patients with ER+ HER2+ tumors?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
What are your top takeaways from ESMO 2023?
How do you address iron replacement during breast cancer treatment?
In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?
Would you send Oncotype for pre-menopausal women with HR+, HER2(-) breast cancer with a small tumor (pT1b) and micrometastatic LN involvement or recommend adjuvant chemotherapy without sending Oncotype?
In a premenopausal, receptor positive node positive woman with breast cancer who has regular menses prior to initiation of chemotherapy and then stops during chemotherapy, how do you determine the timing of ovarian suppression or treatment with medication or oophorectomy?
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?